ATE102956T1 - Polypeptide und deren derivate und deren verwendung in pharmazeutischen und diagnostischen zusammensetzungen. - Google Patents

Polypeptide und deren derivate und deren verwendung in pharmazeutischen und diagnostischen zusammensetzungen.

Info

Publication number
ATE102956T1
ATE102956T1 AT88203040T AT88203040T ATE102956T1 AT E102956 T1 ATE102956 T1 AT E102956T1 AT 88203040 T AT88203040 T AT 88203040T AT 88203040 T AT88203040 T AT 88203040T AT E102956 T1 ATE102956 T1 AT E102956T1
Authority
AT
Austria
Prior art keywords
polypeptides
sequence
derivatives
polypeptide
amino acid
Prior art date
Application number
AT88203040T
Other languages
English (en)
Inventor
Eden Willem Van
Embden Johannes Dirk Antho Van
Der Zee Ruurd Van
Irun Robert Cohen
Original Assignee
Nederlanden Staat
Univ Utrecht
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nederlanden Staat, Univ Utrecht, Yeda Res & Dev filed Critical Nederlanden Staat
Application granted granted Critical
Publication of ATE102956T1 publication Critical patent/ATE102956T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT88203040T 1987-12-22 1988-12-21 Polypeptide und deren derivate und deren verwendung in pharmazeutischen und diagnostischen zusammensetzungen. ATE102956T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL8703107A NL8703107A (nl) 1987-12-22 1987-12-22 Polypeptiden en derivaten daarvan, alsmede de toepassing daarvan in farmaceutische en diagnostische preparaten.
EP88203040A EP0322990B1 (de) 1987-12-22 1988-12-21 Polypeptide und deren Derivate und deren Verwendung in pharmazeutischen und diagnostischen Zusammensetzungen

Publications (1)

Publication Number Publication Date
ATE102956T1 true ATE102956T1 (de) 1994-04-15

Family

ID=19851135

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88203040T ATE102956T1 (de) 1987-12-22 1988-12-21 Polypeptide und deren derivate und deren verwendung in pharmazeutischen und diagnostischen zusammensetzungen.

Country Status (12)

Country Link
US (2) US5154923A (de)
EP (1) EP0322990B1 (de)
JP (1) JPH02797A (de)
AT (1) ATE102956T1 (de)
AU (1) AU614004B2 (de)
CA (1) CA1325612C (de)
DE (1) DE3888502D1 (de)
DK (1) DK714788A (de)
IL (1) IL88750A (de)
NL (1) NL8703107A (de)
NO (1) NO885664L (de)
ZA (1) ZA889486B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4976958A (en) * 1987-02-26 1990-12-11 Scripps Clinic And Research Foundation Mycobacterial recombinants and peptides
NL8703107A (nl) * 1987-12-22 1989-07-17 Nederlanden Staat Polypeptiden en derivaten daarvan, alsmede de toepassing daarvan in farmaceutische en diagnostische preparaten.
US5114844A (en) * 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions
US6897287B1 (en) * 1990-01-31 2005-05-24 Oklahoma Medical Research Foundation Ro/SSA peptide reagents for diagnosis of autoantibodies
US6232522B1 (en) 1990-01-31 2001-05-15 Oklahoma Medical Research Foundation Non-human animal model for systemic lupus erythematosis
GB2251186A (en) * 1990-12-04 1992-07-01 Randall Neal Gatz Polypeptide for use in treatment of autoimmune disease
IL102687A (en) * 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
WO1994003478A1 (en) * 1992-07-31 1994-02-17 Immulogic Pharmaceutical Corporation Sensitive assay for antigens and antibodies and its use to identify rheumatoid arthritis antigen
WO1994007517A1 (en) 1992-10-02 1994-04-14 Alberta Research Council Anti-inflammatory tolerogenic and immunoinhibiting properties of carbohydrate binding-peptides
US5453272A (en) * 1992-10-02 1995-09-26 Alberta Research Council Lectin derived carbohydrate binding-peptide
ATE212378T1 (de) 1993-06-04 2002-02-15 Whitehead Biomedical Inst Stressproteine und ihre verwendung
ES2313719T3 (es) 1993-11-23 2009-03-01 The Regents Of The University Of California Productos extracelulares abundantes y procedimiento de produccion y uso de los mismos.
US6752993B1 (en) 1993-11-23 2004-06-22 The Regents Of The University Of California Abundant extracellular product vaccines and methods for their production and use
US7300660B2 (en) * 1993-11-23 2007-11-27 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
US7888458B1 (en) * 1993-11-30 2011-02-15 John B. Harley Diagnostics and therapy of epstein-barr virus in autoimmune disorders
ES2216009T3 (es) * 1994-03-21 2004-10-16 Rijksuniversiteit Utrecht Fragmentos peptidicos de proteinas de estres microbianas y composicion farmaceutica a base de estos para el tratamiento y la prevencion de enfermedades inflamatorias.
US5869058A (en) * 1994-05-25 1999-02-09 Yeda Research And Development Co. Ltd. Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
HU220746B1 (hu) * 1994-06-17 2002-05-28 Instituut Voor Veehouderij En Diergezondheid Pestivírustörzsekből izolált nukleotidszekvenciák, az általuk kódolt polipeptidek és ezek alkalmazása pestivírus-fertőzések diagnosztizálására és megelőzésére
US5776692A (en) * 1995-05-23 1998-07-07 Baylor College Of Medicine Mycobacterial genus-specific DNA probe and its expressed product
US5843664A (en) * 1996-06-11 1998-12-01 Institut Pasteur Method of selection of allelic exchange mutants
US6013660A (en) * 1996-10-02 2000-01-11 The Regents Of The University Of California Externally targeted prophylactic and chemotherapeutic method and agents
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
US7273613B1 (en) 1997-01-13 2007-09-25 The Board of Regents, The University of Oklahoma Diagnostics and therapy of Epstein-Barr virus in autoimmune disorders
ATE231917T1 (de) 1997-08-05 2003-02-15 Stressgen Biotechnologies Corp Immunresponse gegen hpv antigene erregt von zusammensetzungen die ein hpv antigen und ein stressprotein enthalten oder einen expressionsvektor fähig zur expression dieser proteine
US6007821A (en) * 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
EP0947524A1 (de) * 1998-03-30 1999-10-06 Upither B.V. Neue Peptide zur Behandlung von Autoimmunkrankheiten
US6497880B1 (en) 1998-12-08 2002-12-24 Stressgen Biotechnologies Corporation Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
US6638518B1 (en) 1999-02-22 2003-10-28 University Of Iowa Research Foundation Method for inhibiting inflammatory responses
EP1196772A2 (de) 1999-07-08 2002-04-17 Stressgen Biotechnologies Corporation Induktion einer th1-vermittelten immunantwort in vitro
AU1814101A (en) 2000-01-14 2001-07-24 Massachusetts Institute Of Technology In vivo CTL elicitation by heat shock protein fusion proteins maps to a discrete ATP binding domain and is CD4+ cell-independent
US6812205B2 (en) 2000-03-15 2004-11-02 The Brigham & Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
IL153474A0 (en) 2000-06-26 2003-07-06 Stressgen Biotechnologies Corp Human papilloma virus treatment
WO2002062959A2 (en) 2001-02-05 2002-08-15 Stressgen Biotechnologies Corp. Hepatitis b virus treatment
EP1386155A4 (de) * 2001-04-10 2006-05-10 Univ Leland Stanford Junior Therapeutische und diagnostische verwendungen von antikörperspezifitätsprofilen
AU2003230181A1 (en) 2002-05-21 2003-12-02 Yeda Research And Development Co. Ltd. Dna vaccines encoding heat shock proteins
US20060142251A1 (en) * 2002-11-15 2006-06-29 Gunther Harth Anti-microbial agents derived from methionine sulfoximine analogues
US20050137156A1 (en) * 2003-08-09 2005-06-23 Johnston Stephen A. Methods and compositions for generating an immune response
US8389694B2 (en) * 2003-11-25 2013-03-05 Amanda L. Blasius Biologically active antibodies recognizing a cell surface molecule selectively expressed on living mouse natural type one (I) interferon producing cells
KR20050056799A (ko) * 2003-12-10 2005-06-16 엘지.필립스 엘시디 주식회사 액정 표시패널의 실 패턴 구조
CU23504A1 (es) 2004-09-24 2010-04-13 Ct Ingenieria Genetica Biotech Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas
EP1835933A4 (de) 2005-01-04 2015-01-07 Yeda Res & Dev Hsp60, hsp60-peptide und t-zellen-impfstoffe zur immunmodulation
CA2601518A1 (en) * 2005-03-14 2006-09-21 Irun R. Cohen Compositions of hsp60 peptides and viral antigens for vaccination and diagnosis
EP2007427A4 (de) 2006-04-11 2012-04-04 Yeda Res & Dev Verbesserte impfstoffe mit multimeren hsp60-peptid-trägern
JP2008189637A (ja) 2007-02-08 2008-08-21 Snow Brand Milk Prod Co Ltd 自己免疫疾患予防剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2487198A1 (fr) * 1980-07-28 1982-01-29 Berri Balzac Sa Nouvelle substance immuno-suppressive, son procede d'isolement et son application en therapeutique
IL71683A0 (en) * 1984-04-27 1984-09-30 Yeda Res & Dev Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria
GB8508685D0 (en) * 1985-04-03 1985-05-09 Minor P D Peptides
US4689397A (en) * 1985-08-12 1987-08-25 Scripps Clinic And Research Foundation Synthetic polypeptides for detecting mycobacterial infections
US4772685A (en) * 1985-10-02 1988-09-20 Merck & Co., Inc. Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
US4777239A (en) * 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
NL8701163A (nl) * 1986-09-09 1988-04-05 Nederlanden Staat Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits.
US4952395A (en) * 1987-02-26 1990-08-28 Scripps Clinic And Research Foundation Mycobacterial recombinants and peptides
NL8703107A (nl) * 1987-12-22 1989-07-17 Nederlanden Staat Polypeptiden en derivaten daarvan, alsmede de toepassing daarvan in farmaceutische en diagnostische preparaten.

Also Published As

Publication number Publication date
EP0322990A1 (de) 1989-07-05
DK714788D0 (da) 1988-12-21
IL88750A (en) 1994-01-25
AU2732788A (en) 1989-06-22
AU614004B2 (en) 1991-08-15
DK714788A (da) 1989-06-23
US5154923A (en) 1992-10-13
CA1325612C (en) 1993-12-28
JPH02797A (ja) 1990-01-05
ZA889486B (en) 1989-09-27
NL8703107A (nl) 1989-07-17
NO885664L (no) 1989-06-23
DE3888502D1 (de) 1994-04-21
NO885664D0 (no) 1988-12-21
US5354691A (en) 1994-10-11
EP0322990B1 (de) 1994-03-16

Similar Documents

Publication Publication Date Title
DE3888502D1 (de) Polypeptide und deren Derivate und deren Verwendung in pharmazeutischen und diagnostischen Zusammensetzungen.
ATE198754T1 (de) Antikörper gegen saugetier-interleukin-4 und peptide verwendbar als antigenen für deren herstellung
NO863050L (no) Fremgangsmaate for fremstilling av erytropoietin.
DE3681466D1 (de) Insulin-receptor, seine reinigung, seine herstellung in rekombinanten zellen, dna hierfuer, antikoerper gegen den insulin-receptor und deren herstellung, sowie pharmazeutische zusammensetzungen, die diese antikoerper enthalten.
ATE188251T1 (de) T-zellenrezeptor, spezifisch für antigenpolypeptide und verwandte polynukleotide
DE69434067D1 (de) Menschliche neuronale nikotin-acetylcholin-rezeptor-verbindungen und methoden ihres einsatzes
ATE6251T1 (de) Acylpeptide und pharmazeutische praeparate davon, sowie deren herstellung und verwendung.
ATE404668T1 (de) Wachstumsfaktor-homologe zvegf-3
ATE250133T1 (de) Verktorvermittelte genominsertion und expression von dna in bcg
DE68925869D1 (de) Modifizierte Proteine, modifizierte Interferone alpha- und beta-phosphorylierte Proteine, DNA-Sequenzen und Analoge und deren Verwendung
DE3687761D1 (de) Herstellung des menschlichen von-willebrand-faktors durch rekombinante dns.
DE3850654D1 (de) Immunglobulin-e-kompetitor.
ATE196775T1 (de) Gereinigte flt3 liganden von saeugentieren, agonisten und antagonisten davon
Fullmer et al. The purification of calcium-binding protein from the uterus of the laying hen
SE8505920D0 (sv) New protein and its use
PT87537A (pt) Process for the preparation of cyclic anticoagulant peptides
DE3881023D1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
PT87536A (pt) Process for the preparation of cyclic anticoagulant peptides
ATE190351T1 (de) Polypeptide, von endonexin 2 stammend, mit hepatitis b virus rezeptor aktivität und deren verwendungen in diagnotischen und pharmazeutischen zusammensetzungen
US20060217302A1 (en) Paralytic peptide for use in neuromuscular therapy
DE69233673D1 (de) Protein S polypeptide und deren Verwendungen
DE69232975D1 (de) Protein p100von menschlichem Herpesvirus Typ 6, die korrespondierenden DNS Squenzen, ihre Herstellung und Verwendung
ATE108207T1 (de) Polypeptide und dafür kodierende dna.
RU92016519A (ru) Полипептид, днк, клетка, способ получения полипептида, лекарственное средство, фармацевтическая композиция, применение полипептида

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties